Nina Wressnigg

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl et al. · The Lancet · 2023 · 192 citations · Full text

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial

Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger et al. · The Lancet Infectious Diseases · 2013 · 100 citations

Vaccination, Vaccine Safety, Vaccine Development +9

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial

Nina Wressnigg, Romana Hochreiter, Oliver Zoihsl et al. · The Lancet Infectious Diseases · 2020 · 98 citations

Vaccination, Vaccine Safety, Vaccinology +7

Single HA2 Mutation Increases the Infectivity and Immunogenicity of a Live Attenuated H5N1 Intranasal Influenza Vaccine Candidate Lacking NS1

Brigitte M. Krenn, Andrej Egorov, Ekaterina Romanovskaya-Romanko et al. · PLoS ONE · 2011 · 83 citations · Full text

Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial

Christopher Adlbrecht, Raphael Wurm, Pieter Depuydt et al. · Critical Care · 2020 · 76 citations · Full text